Answers are grounded in this paper and cite their sources.
Pulmonary arterial hypertension (PAH) is a progressive vasculopathy driven by pulmonary vascular remodeling that leads to right ventricular failure and premature death. Despite improvements with therapies targeting the three canonical vasoactive pathways (nitric oxide, endothelin, and prostacyclin)─including endothelin receptor antagonists, phosphodiesterase type-5 inhibitors, soluble guanylyl cyclase stimulators, and prostacyclin analogues─most patients do not achieve disease remission. This highlights the critical need for disease-modifying approaches that directly target and reverse pathological vascular remodeling. Recent advances, including the approval of the activin-signaling inhibitor sotatercept, suggest the feasibility of strategies that target novel antiremodeling pathways; however, PAH remains incurable for the vast majority. Neuropilin-1 (NRP1) is a multifunctional coreceptor expressed by endothelial cells (ECs) and pulmonary artery smooth muscle cells (PASMCs). The receptor orchestrates intracellular signaling by binding multiple ligands implicated in PAH pathobiology, including vascular endothelial growth factor (VEGF)-A, transforming growth factor (TGF)-β family members and platelet-derived growth factors (PDGFs), and modulates endothelial junctional stability, permeability and smooth muscle cell migration Here, we show that NRP1 is overexpressed in pulmonary artery smooth muscle cells from patients with PAH and that pharmacological inhibition of NRP1 with the novel small-molecule antagonist EG00229 attenuates hemodynamic and structural features of the disease in the gold-standard Sugen 5416/hypoxia (SuHx) mouse model of PAH. EG00229 reduced right-ventricular systolic pressure, right ventricular hypertrophy, and pulmonary arterial muscularization without affecting systemic blood pressure or body weight, supporting on-target pulmonary selectivity. These findings identify NRP1 as a tractable therapeutic target with potential to modulate vascular remodeling in PAH.
No takes yet. Share an insight, caveat, or question.
Berg et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: